B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

B. Riley Securities analyst Yuan Zhi has maintained a 'Buy' rating on Perspective Therapeutics (AMEX: CATX) and increased the price target from $11 to $13. This adjustment reflects a positive outlook on the company's performance.